Evolus (EOLS) director awarded 45,559 restricted stock units in Form 4 filing

Rhea-AI Filing Summary

Parschauer Karah Herdman reported acquisition or exercise transactions in this Form 4 filing.

Evolus, Inc. director Karah Herdman Parschauer reported an equity compensation grant in the form of restricted stock units (RSUs). The filing shows an award of 45,559 shares of common stock at a price of $0.00 per share, bringing her directly owned total to 77,742 shares.

According to the disclosure, these 45,559 RSUs each represent a contingent right to receive one share of Evolus common stock. The RSUs are scheduled to vest in full on the one year anniversary of February 17, 2026, if she remains in continuous service through the vesting date, with potential accelerated vesting in certain change-of-control and other specified events.

Insights

Equity Compensation Analyst

Director receives time-based RSU grant as routine equity compensation.

The transaction reflects a grant or award acquisition of 45,559 restricted stock units of Evolus, Inc. common stock at $0.00 per share to director Karah Herdman Parschauer. This is a non-cash compensation event, consistent with standard board equity incentives.

The RSUs vest in full on the one year anniversary of February 17, 2026, conditioned on continued service, with provisions for accelerated vesting upon certain changes of control or other events. Such structures are designed to align director interests with shareholders over time.

Given the absence of any open-market buying or selling and the time-based vesting conditions, this filing is best viewed as routine governance-related compensation disclosure rather than a directional signal about insider sentiment or near-term company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parschauer Karah Herdman

(Last) (First) (Middle)

520 NEWPORT CENTER DRIVE

SUITE 1200

(Street)

NEWPORT BEACH CA 92660

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evolus, Inc. [ EOLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		45,559(1)	A	$0	77,742	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.

Remarks:

	/s/ Jeffrey J. Plumer, as attorney-in-fact for Karah Parschauer	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Evolus (EOLS) report in this Form 4?

Evolus reported that director Karah Herdman Parschauer received a grant of 45,559 restricted stock units. Each unit represents a contingent right to one share of common stock, with no cash paid per share for this equity compensation award.

How many Evolus (EOLS) shares does the director hold after this RSU grant?

After the reported RSU grant, the Form 4 lists 77,742 shares of Evolus common stock as directly owned. This total reflects the effect of the 45,559-share restricted stock unit award disclosed in the filing, assuming all conditions described remain in place.

What are the vesting terms of the 45,559 Evolus (EOLS) RSUs?

The 45,559 restricted stock units will vest in full on the one year anniversary of February 17, 2026. Vesting requires the director to remain in continuous service through that date, with accelerated vesting possible upon certain change-of-control and other specified events for Evolus.

Did the Evolus (EOLS) director buy or sell shares on the open market?

The Form 4 does not show any open-market purchase or sale. Instead, it reports a grant or award acquisition of restricted stock units at $0.00 per share, reflecting stock-based compensation rather than a discretionary market trade by the Evolus director.

What does the Form 4 footnote say about the Evolus (EOLS) RSUs?

The footnote explains that each RSU represents a contingent right to receive one share of Evolus common stock. It also notes that vesting depends on continuous service and may accelerate in certain events, including specified change-of-control situations affecting the company.